- Oramed Pharmaceuticals Inc ORMP has announced additional data from its Phase 2 trial (ORA-D-N02) of oral insulin candidate (ORMD-0801) to reduce liver fat content in Type 2 Diabetes patients with non-alcoholic steatohepatitis (NASH).
- Overall, the Phase 2 trial proved that ORMD-0801 might be a potential candidate for reducing liver fat, stiffness, and lipids in patients with T2D and NASH.
- Related: Oramed Oral Insulin Shows Evidence For NASH Treatment.
- The whole Liver showed a placebo-adjusted mean decrease in liver fat content of 0.96 with a placebo-adjusted median decrease of 6.0 for ORMD-0801.
- Median Change from Baseline to Week 12 in Fibrosis Median (kPa) showed a placebo-adjusted median decrease of 1.1 for ORMD-0801.
- Median change from Baseline to Week 12 in Steatosis Median (dB/m) showed a placebo-adjusted median decrease of 29 for ORMD-0801.
- The mean Change from Baseline to Week 12 in Total Cholesterol (mmol/L) showed a placebo-adjusted mean decrease of 0.40 for ORMD-0801. Results were similar for LDL, HDL, and Triglycerides.
- Price Action: ORMP shares are down 3.40% at $7.95 on the last check Thursday.
© 2023 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.